Texas A&M Biologists Celebrate Biotech Start-Up’s $1.4 Billion Sale

Dec 23, 2019
“Due to Roche’s strong expertise in IPF, hematological cancer and other fibrotic disorders, we believe Roche is ideally positioned to bring the potential of our platform to patients and provide new treatment options within these areas of urgent unmet medical need."
Jason Lettmann, CEO of Promedior